Key Points
- CAO Deborah Stewart sold 34,616 shares across three trades (Dec. 30–Jan. 2) for about $281,260 total, leaving her with 263,638 shares (a ~4.1% reduction) valued at roughly $2.16 million.
- Multiple senior insiders — including the CEO and CFO — also sold large blocks of shares (~tens of thousands each) over Dec. 30–Jan. 2, a pattern that may pressure sentiment by increasing perceived supply.
- Aveanna (NASDAQ:AVAH) is trading around $8.08 with a market cap of about $1.69 billion and a consensus analyst rating of Hold and a $10.69 average price target.
Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Get Free Report) CAO Deborah Stewart sold 11,275 shares of the firm's stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $8.18, for a total value of $92,229.50. Following the completion of the sale, the chief accounting officer directly owned 263,638 shares of the company's stock, valued at $2,156,558.84. This represents a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Deborah Stewart also recently made the following trade(s):
- On Friday, January 2nd, Deborah Stewart sold 11,962 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.85, for a total value of $93,901.70.
- On Tuesday, December 30th, Deborah Stewart sold 11,379 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.36, for a total value of $95,128.44.
Aveanna Healthcare Trading Down 1.1%
Shares of AVAH opened at $8.08 on Friday. Aveanna Healthcare Holdings Inc. has a fifty-two week low of $3.67 and a fifty-two week high of $10.32. The business has a 50-day moving average of $8.92 and a 200 day moving average of $7.49. The firm has a market cap of $1.69 billion, a P/E ratio of 22.44 and a beta of 2.06. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23.
Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) last issued its earnings results on Monday, May 22nd. The company reported $0.04 earnings per share for the quarter. The firm had revenue of $450.53 million during the quarter. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. As a group, research analysts forecast that Aveanna Healthcare Holdings Inc. will post -0.06 EPS for the current year.
Trending Headlines about Aveanna Healthcare
Here are the key news stories impacting Aveanna Healthcare this week:
- Negative Sentiment: CEO Jeff Shaner sold multiple blocks (roughly 83,000+ shares across Dec. 30–Jan. 2 in the filings), at prices around $8.18–$8.36, reducing his stake by about 1–1.2% in individual trades while retaining a multi‑million‑share holding — investors may view repeated CEO sales as a negative signal. SEC filing — Jeff Shaner
- Negative Sentiment: CFO Matthew Buckhalter executed several sales (totaling ~70,000+ shares across Dec. 30–Jan. 2) at roughly $7.85–$8.36, each reducing his position by ~3.5–4%. Repeated CFO sales can raise governance/comfort concerns for short‑term holders. SEC filing — Matthew Buckhalter
- Negative Sentiment: CAO Deborah Stewart sold multiple blocks (~34,000+ shares across Dec. 30–Jan. 2) at similar price levels, trimming her stake by ~4% in reported trades while keeping a substantial holding — another senior exec sale that may pressure sentiment. SEC filing — Deborah Stewart
- Negative Sentiment: Insider Edwin C. Reisz sold multiple tranches (~51,000+ shares across Dec. 30–Jan. 2) at $7.85–$8.36, reducing his position by ~1.2% in several filings. Multiple insider sellers across ranks amplify negative interpretation. SEC filing — Edwin C. Reisz
- Negative Sentiment: Insider Patrick A. Cunningham reported several sales (~36,000+ shares across Dec. 30–Jan. 2) at similar price points, lowering his stake by ~3.6–4.1% in the disclosed trades. Collective insider selling increases perceived supply risk. SEC filing — Patrick A. Cunningham
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on AVAH shares. Royal Bank Of Canada boosted their target price on shares of Aveanna Healthcare from $8.00 to $10.00 and gave the company a "sector perform" rating in a report on Friday, October 24th. William Blair started coverage on Aveanna Healthcare in a research note on Monday, December 8th. They set an "outperform" rating on the stock. JPMorgan Chase & Co. raised Aveanna Healthcare from an "underweight" rating to a "neutral" rating and increased their price objective for the stock from $6.00 to $10.00 in a report on Thursday, September 18th. Raymond James Financial reaffirmed an "outperform" rating and set a $13.00 target price on shares of Aveanna Healthcare in a report on Friday, December 5th. Finally, UBS Group upped their price target on Aveanna Healthcare from $9.00 to $9.50 and gave the company a "neutral" rating in a research report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $10.69.
Read Our Latest Report on AVAH
Institutional Trading of Aveanna Healthcare
Large investors have recently modified their holdings of the business. Summit Partners L P purchased a new position in shares of Aveanna Healthcare during the second quarter worth about $50,477,000. Vanguard Group Inc. lifted its position in Aveanna Healthcare by 34.7% during the third quarter. Vanguard Group Inc. now owns 4,041,659 shares of the company's stock valued at $35,850,000 after purchasing an additional 1,041,324 shares during the last quarter. AustralianSuper Pty Ltd purchased a new position in Aveanna Healthcare in the 3rd quarter worth approximately $15,743,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Aveanna Healthcare by 70.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,130,912 shares of the company's stock worth $10,031,000 after buying an additional 466,022 shares in the last quarter. Finally, Algert Global LLC increased its holdings in shares of Aveanna Healthcare by 120.1% in the 3rd quarter. Algert Global LLC now owns 1,022,599 shares of the company's stock worth $9,070,000 after buying an additional 557,898 shares during the last quarter. Institutional investors own 87.96% of the company's stock.
About Aveanna Healthcare
(
Get Free Report)
Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna's offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.
In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
